Takashi Kei Kishimoto, PhD

Articles by Takashi Kei Kishimoto, PhD

Re-Dosing With Gene Therapies in Rare Diseases

ByTakashi Kei Kishimoto, PhD,Carsten Brunn, PhD

June 15th 2022

Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.

Takashi Kei Kishimoto, PhD

Articles by Takashi Kei Kishimoto, PhD

Re-Dosing With Gene Therapies in Rare Diseases

Latest Updated Articles

Trending on CGTlive®

FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More